Quanterix (NASDAQ:QTRX) agrees to acquire privately held Uman Diagnostics for $22.5M, comprised of $16M in cash and $6.5M in Quanterix shares
Uman possess antibodies to measure neurofilament light (Nf-L), and the acquisition positions Quanterix to capitalize opportunities with Nf-L applications in Alzheimer’s Disease, Multiple Sclerosis, and other neuro-degenerative conditions
Date: July 01, 2019
SOURCE: Quanterix